Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus
about
A quasi-spontaneous amyloid route in a DNA binding gene regulatory domain: The papillomavirus HPV16 E2 protein.Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesDifferential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialImmunotherapy for cervical cancer: Research status and clinical potentialThe influence of delivery vectors on HIV vaccine efficacyUsing cancer incidence and mortality data to guide cancer control programThe oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors.Immune therapy for human papillomaviruses-related cancers.Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility.Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.The future of vaccines for cervical cancer.Therapeutic Vaccine Strategies against Human Papillomavirus.Progress in the development of a cervical cancer vaccine.Vaccines against cervical cancer.Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.Emerging human papillomavirus vaccines.Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene.Targeted treatments for cervical cancer: a review.Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.Human papillomavirus infection: an old disease, a new vaccine.Gene therapy in gynecological cancer.Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma.Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.Human papillomavirus therapeutic vaccines in head and neck tumors.Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.Progress and challenges in the vaccine-based treatment of head and neck cancers.Therapeutic vaccines against human papillomavirus and cervical cancer.Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 proteinCervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.Perspectives for the development of human papillomavirus vaccines and immunotherapy.Immunologic treatments for precancerous lesions and uterine cervical cancer.Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer.An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia.Current state in the development of candidate therapeutic HPV vaccines
P2860
Q30158017-ADA1E1D7-EA24-40C4-8DDA-6016944504ABQ30238779-BD29567A-D823-452E-BA80-ED3768DF786AQ33440600-5638BA0C-FE78-4EDA-9DC6-7BA768EDE9D2Q33602820-F559DB45-63DE-47F1-B843-FBBE67867D12Q33626255-20F31276-9CF3-47F5-BC49-9D47DF515558Q34033763-6948AD47-F480-4767-9395-B88CC69A0E06Q34077543-5B2F4A3A-7B16-4473-9A2C-D1E168E99A98Q34367530-77E94DB3-48BF-46D9-B5D7-44ABA5D82D47Q34635024-708F44E5-3E11-451F-A785-4983F7B9D87FQ34657561-2867BF1A-7EF9-417E-BAA3-8715C6F5A682Q34729962-4343134C-CAD0-46D8-8115-F291E895AC1CQ35055665-22736593-1516-438E-AB89-C1D6356051C8Q35274806-4C919B97-7E6D-4AD2-8A8A-9360AE8EB4E3Q35751946-C8C84160-1EF7-4C78-B5B6-4A060F5E3636Q35805491-013602E8-6CA9-4962-89F8-4B52D29D3A65Q35826752-DF8ECCAE-CC0D-4901-934D-8437D8C0D4DCQ35919119-3D42B8C6-A033-4F62-B8D0-061D34C59290Q35925621-1B6B39B9-7DB4-4BED-B52D-978AB2AA3228Q35947683-8A9C02D4-84E8-4C43-A720-EA52C9A057C4Q36066004-04FAE0B1-9793-4DC3-9AF9-49E161ADE1EBQ36305188-B53BB3C1-D99D-439C-A2D4-0E1A469D0A20Q36384032-0D91BB2E-EEB1-483C-B90A-C11806DEFA51Q36397581-C62088E3-A280-46FB-A371-532F2BC05979Q36480555-13445642-B665-4E88-BBD9-7427B768CB7FQ36532089-37B370B2-CEA4-486F-8D34-6722F8E5A6F7Q36541670-B9C9C3BC-5589-4F74-8CEE-D224DD561074Q36628376-4DD78606-B8A7-488E-A9CF-2043FB463B59Q36817148-28A1E511-0DF3-4F2D-A404-0139EA82ABC3Q36849770-D3C2D70F-28C4-4B2E-8341-515A51A3E73EQ37118188-39DFE559-FA93-4275-8AA0-809ADBA71A12Q37135023-6E5C75C1-A9EE-4FF7-B332-058C5579C6D6Q37224926-94F92498-670D-4B6C-9C26-B7FE66E68E12Q37418916-590F6EBB-4187-42E2-A830-49FD1033ACFBQ37545001-42F07945-6635-4646-AD25-51F2E314D8CBQ37579334-61F7526F-3727-41E5-9688-D932974F3485Q37658876-A2EB1F75-EEF1-4142-BE7D-532507DB597DQ37703113-31FD9BC2-1DF4-4CDB-BBEE-A0E7E839E50FQ38089937-8D5E04F1-3E93-441F-8744-381A58A524CDQ38386055-A7980925-559A-4C2F-9DAE-39DB940865CCQ38743922-0DD79A3E-615B-41BB-B4A4-E9F3FB43BA2E
P2860
Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@ast
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@en
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@nl
type
label
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@ast
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@en
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@nl
prefLabel
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@ast
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@en
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@nl
P2093
P1433
P1476
Therapeutic vaccination with M ...... oncogenic human papillomavirus
@en
P2093
Alberto Tinoco
Carlos Manuel Corona Gutierrez
Gianni Morosoli
Lise Reyes
Mario López Contreras
Mauro Lara Verde
Patricia Calzado
Ricardo Rosales
Roberto Posternak
Roberto Risco Cortes
P304
P356
10.1089/10430340460745757
P407
P577
2004-05-01T00:00:00Z